Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, initially developed for type 2 diabetes mellitus, might also have cardioprotective properties for heart failure (HF) patients, independent of blood glucose levels. This systematic review and meta-analysis evaluated the effectiveness of SGLT-2 inhibitors in improving outcomes for HF patients, regardless of ejection fraction (EF) status or HF type. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases, such as Embase, Medline, and Global Health, were searched for relevant clinical studies. Nine studies were analyzed with 19,904 participants (11,155 treated with SGLT-2 inhibitors and 8,749 control patients). Results indicated significant improvements in EF and overall heart function with SGLT-2 inhibitors compared to standard care. Future well-designed studies with extended follow-up periods and diverse patient demographics are needed to fully understand the long-term effects and optimize HF management with SGLT-2 inhibitors.
Key words: Ejection fraction, heart failure, kidney function, SGLT-2 Inhibitors.
|
